glp-1 agonist therapy Essentials Semaglutide Advances In GLP 1

A phase 1, randomized, double-blind, placebo-controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects

We observed a reduction in mesenteric white adipose tissue (WAT) in I-M-150847 treated mice (mean % normalized fat mass, control : 0.2752 0.019% n=5 and upon I-M-150847 treatment: 0

These are the same neurotransmitters targeted by most psychiatric medications for depression and anxiety

Survodutide : Phase 2 completed for obesity (Lancet 2024) and MASH (NEJM 2024)

Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): A substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

Nearly 40 million people in the U.S